CN105579059B - 热稳定的疫苗配制物、工艺和包含疫苗配制物的微针 - Google Patents

热稳定的疫苗配制物、工艺和包含疫苗配制物的微针 Download PDF

Info

Publication number
CN105579059B
CN105579059B CN201480052624.6A CN201480052624A CN105579059B CN 105579059 B CN105579059 B CN 105579059B CN 201480052624 A CN201480052624 A CN 201480052624A CN 105579059 B CN105579059 B CN 105579059B
Authority
CN
China
Prior art keywords
vaccine composition
maltodextrin
influenza
vaccine
arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480052624.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105579059A (zh
Inventor
马修·约瑟夫·米斯蒂利斯
威廉·克里斯多佛·埃登斯
安德烈亚斯·塞巴斯蒂安·伯姆马里尤斯
马克·普劳斯尼茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgia Tech Research Corp
Original Assignee
Georgia Tech Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgia Tech Research Corp filed Critical Georgia Tech Research Corp
Publication of CN105579059A publication Critical patent/CN105579059A/zh
Application granted granted Critical
Publication of CN105579059B publication Critical patent/CN105579059B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
CN201480052624.6A 2013-09-03 2014-09-03 热稳定的疫苗配制物、工艺和包含疫苗配制物的微针 Active CN105579059B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361873032P 2013-09-03 2013-09-03
US61/873,032 2013-09-03
US201361873419P 2013-09-04 2013-09-04
US61/873,419 2013-09-04
PCT/US2014/053902 WO2015034924A1 (en) 2013-09-03 2014-09-03 Thermally stable vaccine formulations and microneedles

Publications (2)

Publication Number Publication Date
CN105579059A CN105579059A (zh) 2016-05-11
CN105579059B true CN105579059B (zh) 2020-07-31

Family

ID=52628897

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480052624.6A Active CN105579059B (zh) 2013-09-03 2014-09-03 热稳定的疫苗配制物、工艺和包含疫苗配制物的微针

Country Status (8)

Country Link
US (1) US10736840B2 (cg-RX-API-DMAC7.html)
EP (1) EP3041504B1 (cg-RX-API-DMAC7.html)
JP (2) JP6611720B2 (cg-RX-API-DMAC7.html)
CN (1) CN105579059B (cg-RX-API-DMAC7.html)
CA (1) CA2923010C (cg-RX-API-DMAC7.html)
ES (1) ES2897659T3 (cg-RX-API-DMAC7.html)
RU (1) RU2720808C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015034924A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402131D0 (en) 2004-01-30 2004-03-03 Isis Innovation Delivery method
EP3881781B1 (en) 2011-10-12 2023-03-29 Vaxxas Pty Limited Delivery device
WO2015163488A1 (en) 2014-04-25 2015-10-29 Ajinomoto Co., Inc. Immunostimulating agent
CA2975275C (en) 2015-02-02 2023-08-29 Vaxxas Pty Limited Microprojection array applicator and method
US20160296149A1 (en) * 2015-04-08 2016-10-13 Sandia Corporation In Vivo Extraction of Interstitial Fluid Using Hollow Microneedles
CN104984357B (zh) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗
WO2017045031A1 (en) 2015-09-18 2017-03-23 Vaxxas Pty Limited Microprojection arrays with microprojections having large surface area profiles
EP3355981B1 (en) 2015-09-28 2025-11-19 Vaxxas Pty Limited Microprojection arrays with enhanced skin penetrating properties and methods thereof
BR112018006488B1 (pt) * 2015-10-06 2024-03-12 Janssen Vaccines & Prevention B.V. Métodos para prevenir a degradação induzida por plástico de biológicos
EP3511318A1 (en) 2015-10-28 2019-07-17 Ajinomoto Co., Inc. Immunostimulating agent
US10722570B2 (en) * 2015-11-27 2020-07-28 Nitto Denko Corporation Dried influenza vaccine preparation and method for producing dried influenza vaccine preparation
CN108289948A (zh) * 2015-11-27 2018-07-17 日东电工株式会社 口腔内给药用疫苗药物组合物和口腔内给药用疫苗药物组合物的制造方法
WO2017090767A1 (ja) * 2015-11-27 2017-06-01 日東電工株式会社 インフルエンザワクチン乾燥製剤、及び、インフルエンザワクチン乾燥製剤の製造方法
CN113181106A (zh) * 2016-01-11 2021-07-30 沃达瑞公司 微针组合物及其使用方法
RU2018134360A (ru) 2016-03-01 2020-04-01 Джорджия Тек Рисёч Корпорейшн Микроигольные частицы, композиции и способы лечения и доставки представляющего интерес вещества
WO2018176102A1 (en) 2017-03-31 2018-10-04 Vaxxas Pty Limited Device and method for coating surfaces
CA3065371A1 (en) 2017-06-13 2018-12-20 Vaxxas Pty Limited Quality control of substrate coatings
AU2018309562A1 (en) 2017-08-04 2020-02-20 Vaxxas Pty Limited Compact high mechanical energy storage and low trigger force actuator for the delivery of microprojection array patches (MAP)
AU2018315629B2 (en) * 2017-08-10 2025-06-26 Vaxxas Pty Limited Differential coating of microprojections and microneedles on arrays
CN110870913A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 氨基酸类营养素作为疫苗佐剂的应用以及包含氨基酸营养素作为佐剂的疫苗
CA3130036A1 (en) * 2019-02-15 2020-08-20 Serum Institute Of India Pvt Ltd. Live attenuated influenza vaccine composition and process for preparation thereof
JP7176100B2 (ja) * 2019-03-28 2022-11-21 富士フイルム株式会社 インフルエンザワクチンを含有するマイクロニードルアレイ及びマイクロニードルアレイの製造方法
CN113874067A (zh) * 2019-03-29 2021-12-31 瓦克萨斯私人有限公司 用于疫苗的高密度微突出物阵列贴片
CA3159272A1 (en) * 2019-11-22 2021-05-27 Veradermics Incorporated Microneedle patch for immunostimulatory drug delivery
CN111154833B (zh) * 2020-01-03 2022-08-23 浙江夸克生物科技有限公司 一种α-L-岩藻糖苷酶测定试剂盒
US20230233373A1 (en) * 2020-06-11 2023-07-27 Aquavit Pharmaceuticals, Inc. Methods and compositions for delivering bioactive compositions to ocular tissue using microneedle devices
CN117355356A (zh) * 2021-03-23 2024-01-05 韦瑞德米克斯公司 皮肤病症的病灶周围治疗
JP2024543125A (ja) * 2021-11-25 2024-11-19 オレクソ・アクチエボラゲット バイオ医薬品化合物を含む医薬組成物
WO2025013783A1 (ja) * 2023-07-07 2025-01-16 ナガセヴィータ株式会社 タンパク質の変性抑制用組成物
WO2025222045A1 (en) * 2024-04-17 2025-10-23 Micron Biomedical, Inc. Microneedle devices for vaccinations with enhanced delivery and acceptance

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080286369A1 (en) * 2004-07-27 2008-11-20 University Of Strathclyde Process for Preparing Microcrystals
US20090232894A1 (en) * 2008-03-05 2009-09-17 Sanofi Pasteur Process for Stabilizing an Adjuvant Containing Vaccine Composition
US20110081380A1 (en) * 2009-10-07 2011-04-07 Sanofi Pasteur Stabilizing Excipient for Inactivated Whole Virus Vaccine
US20110243988A1 (en) * 2009-10-01 2011-10-06 Aridis Pharmaceuticals Methods and Compositions for Stabilization of a Virus Vaccine
WO2012145739A1 (en) * 2011-04-21 2012-10-26 Trustees Of Tufts College Compositions and methods for stabilization of active agents
WO2013082418A1 (en) * 2011-11-30 2013-06-06 3M Innovative Properties Company Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
AU767122B2 (en) 1998-06-10 2003-10-30 Georgia Tech Research Corporation Microneedle devices and methods of manufacture and use thereof
US6743211B1 (en) 1999-11-23 2004-06-01 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
US6623457B1 (en) 1999-09-22 2003-09-23 Becton, Dickinson And Company Method and apparatus for the transdermal administration of a substance
US9302903B2 (en) 2000-12-14 2016-04-05 Georgia Tech Research Corporation Microneedle devices and production thereof
US6887484B2 (en) * 2001-07-31 2005-05-03 Posco Vaccine composition containing a promoter peptide
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
AU2003275311A1 (en) 2002-09-16 2004-04-30 Sung-Yun Kwon Solid micro-perforators and methods of use
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
AU2004251699A1 (en) 2003-06-04 2005-01-06 Georgia Tech Research Corporation Drilling microneedle device
US9744227B2 (en) 2004-06-02 2017-08-29 Universal Stabilization Technologies, Inc. Compositions containing ambient-temperature stable, inactivated but therapeutically active biopharmaceuticals and methods for formulation thereof
US20080269666A1 (en) 2005-05-25 2008-10-30 Georgia Tech Research Corporation Microneedles and Methods for Microinfusion
WO2006138719A2 (en) 2005-06-17 2006-12-28 Georgia Tech Research Corporation Coated microstructures and method of manufacture thereof
HRP20110803T1 (hr) 2005-09-16 2011-11-30 Merial Ltd. Stabilizatori za cjepiva osušena zamrzavanjem
US20090182306A1 (en) 2006-07-21 2009-07-16 Georgia Tech Research Corporation Microneedle Devices and Methods of Drug Delivery or Fluid Withdrawal
KR20090128463A (ko) 2007-03-09 2009-12-15 오츠카 세이야쿠 가부시키가이샤 인플루엔자 백신 함유 동결 건조 제제, 및 그의 제조 방법
WO2009048607A1 (en) 2007-10-10 2009-04-16 Corium International, Inc. Vaccine delivery via microneedle arrays
GB0725018D0 (en) 2007-12-21 2008-01-30 Univ Cardiff Monitoring system for microneedle delivery
MX2010009351A (es) 2008-02-25 2011-03-04 Novavax Inc Particulas similares a virus cristalizadas con azucar.
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
WO2010001671A1 (ja) 2008-06-30 2010-01-07 久光製薬株式会社 マイクロニードルデバイスおよびマイクロニードルデバイスによるインフルエンザワクチンの奏功性を上昇させる方法
RU2577698C2 (ru) * 2009-03-26 2016-03-20 Пулмэтрикс, Инк. Сухие порошкообразные составы и способы лечения легочных заболеваний
WO2011014794A1 (en) * 2009-07-31 2011-02-03 Paxvax, Inc. Adenoviral-based vectors
ES2543795T3 (es) 2010-03-31 2015-08-21 Stabilitech Ltd. Estabilización de partículas virales
CA2796593C (en) 2010-04-15 2020-12-15 Shin Nippon Biomedical Laboratories, Ltd. Methods and compositions for intranasal delivery
GB201007207D0 (en) 2010-04-29 2010-06-16 Univ Cork Method
JP5976639B2 (ja) 2010-06-01 2016-08-23 ノバルティス アーゲー インフルエンザワクチン抗原の濃縮および凍結乾燥
WO2011156641A2 (en) 2010-06-09 2011-12-15 Kaspar Roger L Microneedle arrays for active agent delivery
JP5808102B2 (ja) 2010-07-22 2015-11-10 コスメディ製薬株式会社 抗原を含有する経皮免疫製剤およびその製造方法
CA2808965C (en) 2010-08-20 2020-01-07 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
JP5558311B2 (ja) 2010-10-27 2014-07-23 株式会社バイオセレンタック ワクチン抗原表皮デリバリー用溶解性３層マイクロニードル・アレイ・パッチ
WO2012103257A2 (en) 2011-01-25 2012-08-02 The Regents Of The University Of California Transcutaneous multimodal delivery systems
KR102374576B1 (ko) 2011-05-17 2022-03-15 솔리제닉스, 인크. 열안정성 백신 조성물 및 그의 제조방법
US20130096532A1 (en) 2011-10-17 2013-04-18 Rutgers, The State University Of New Jersey Polymer-Based Micro-Needle Array Designs, Fabrication Processes, and Methods of Use Thereof for Drug Delivery
WO2013152092A1 (en) 2012-04-03 2013-10-10 Theraject, Inc. Soluble microneedle arrays for buccal delivery of vaccines
WO2014004462A1 (en) 2012-06-25 2014-01-03 Flugen, Inc. Multiple drug delivery device
CA2906945A1 (en) 2013-03-15 2014-09-18 Incube Labs, Llc Multi-stage biodegradable drug delivery platform
NZ731659A (en) 2014-11-03 2018-10-26 Merial Inc Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080286369A1 (en) * 2004-07-27 2008-11-20 University Of Strathclyde Process for Preparing Microcrystals
US20090232894A1 (en) * 2008-03-05 2009-09-17 Sanofi Pasteur Process for Stabilizing an Adjuvant Containing Vaccine Composition
US20110243988A1 (en) * 2009-10-01 2011-10-06 Aridis Pharmaceuticals Methods and Compositions for Stabilization of a Virus Vaccine
US20110081380A1 (en) * 2009-10-07 2011-04-07 Sanofi Pasteur Stabilizing Excipient for Inactivated Whole Virus Vaccine
WO2012145739A1 (en) * 2011-04-21 2012-10-26 Trustees Of Tufts College Compositions and methods for stabilization of active agents
WO2013082418A1 (en) * 2011-11-30 2013-06-06 3M Innovative Properties Company Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Development of Stable Influenza Vaccine Powder Formulations: Challenges and Possibilities;J-P. Amorij 等;《Pharmaceutical Research》;20080313;第25卷(第6期);第1256-1273页 *
Dissolvable Microneedle Patches for the Delivery of Cell-Culture-Derived Influenza Vaccine Antigens;SUSHMA KOMMAREDDY 等;《JOURNAL OF PHARMACEUTICAL SCIENCES》;20111220;第101卷(第3期);第1021页摘要、第1022页图1、第1023页左栏第1段 *
Dissolving polymer microneedle patches for influenza vaccination;Sean P Sullivan 等;《Nature Medicine》;20100718;第16卷(第8期);第915页摘要、第916页图1和2、 Online Methods *
Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity;Yeu-Chun Kim 等;《Journal of Controlled Release》;20091017;第142卷;第187页摘要、第187页第2.2-2.4节、第189页图1 *
Microneedles for drug and vaccine delivery;Yeu-Chun Kim 等;《Advanced Drug Delivery Reviews》;20120501;第64卷;第1556页第3.1.3.2.1节 *

Also Published As

Publication number Publication date
RU2720808C2 (ru) 2020-05-13
JP7358068B2 (ja) 2023-10-10
CN105579059A (zh) 2016-05-11
JP2016535065A (ja) 2016-11-10
US20160220483A1 (en) 2016-08-04
EP3041504A1 (en) 2016-07-13
CA2923010C (en) 2022-08-30
RU2016111354A (ru) 2017-10-09
JP2019163271A (ja) 2019-09-26
US10736840B2 (en) 2020-08-11
CA2923010A1 (en) 2015-03-12
JP6611720B2 (ja) 2019-11-27
EP3041504B1 (en) 2021-08-25
EP3041504A4 (en) 2018-02-21
WO2015034924A1 (en) 2015-03-12
ES2897659T3 (es) 2022-03-02
RU2016111354A3 (cg-RX-API-DMAC7.html) 2018-07-16

Similar Documents

Publication Publication Date Title
CN105579059B (zh) 热稳定的疫苗配制物、工艺和包含疫苗配制物的微针
Kim et al. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity
Dumpa et al. Stability of vaccines
Amorij et al. Development of stable influenza vaccine powder formulations: challenges and possibilities
Kim et al. Formulation of microneedles coated with influenza virus-like particle vaccine
JP7051132B2 (ja) ワクチン接種または遺伝子治療のための効率的なウイルスベクターベースの組成物を得るための新規方法
US20100015177A1 (en) Method for Preserving Viral Particles
KR20130083376A (ko) 비강내 전달을 위한 방법 및 조성물
de Jonge et al. Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage
HUP0202846A2 (hu) Intranazális influenzavírus-oltóanyag
RU2484847C2 (ru) Лиофилизированный препарат, содержащий гриппозную вакцину, и способ его получения
CN102939104A (zh) 用冻干浓缩疫苗抗原
JP2016534070A (ja) 安定化ワクチンの製造のための新規方法
WO2019118393A1 (en) Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
KR20050105468A (ko) 바이로솜-같은-입자
US20250057936A1 (en) Vaccine composition
US20220325250A1 (en) Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
ES2731636T3 (es) Composición adyuvante que contiene citrulina
JP7602457B2 (ja) ペプチド核酸を基盤としたアジュバント
Beukema Intradermal administration of influenza accine ith trehalose and pullulan-based dissol ing microneedle arra s
Soema Formulation of influenza T cell peptides: in search of a universal influenza vaccine
Mistilis Thermostabilization of Influenza Vaccine in Microneedle Patches
Amorij The development of stable influenza vaccine powder formulations for new needle-free dosage forms
Edens MEASLES AND POLIO VACCINATION USING A MICRONEEDLE PATCH TO INCREASE VACCINATION COVERAGE IN THE DEVELOPING WORLD
Amorij et al. Development of stable influenza vaccine powder formulations for non-parenteral dosage forms: challenges and possibilities.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant